Christian Brieghel

Christian Brieghel

Auto-generated profile, based on publicly available information

Christian Brieghel

Department of Hematology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
AAAndreas Agathangelidis
Andreas Agathangelidis
ACAnastasia Chatzidimitriou
Anastasia Chatzidimitriou
KGKaterina Gemenetzi
Katerina Gemenetzi
VGVéronique Giudicelli
Véronique Giudicelli
MKMaria Karypidou
Maria Karypidou
KSKostas Stamatopoulos
Kostas Stamatopoulos
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed “satellites,” were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.

17 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RARudi Agius
Rudi Agius
CBChristian Brieghel
Christian Brieghel
MAMichael A. Andersen
Michael A. Andersen
APAlexander T. Pearson
Alexander T. Pearson
BLBruno Ledergerber
Bruno Ledergerber
CNCarsten U. Niemann
Carsten U. Niemann
Infections have become the major cause of morbidity and mortality among patients with chronic lymphocytic leukemia (CLL) due to immune dysfunction and cytotoxic CLL treatment. Yet, predictive models for infection are missing. In this work, we develop the CLL Treatment-Infection Model (CLL-TIM) that identifies patients at risk of infection or CLL treatment within 2 years of diagnosis as validated on both internal and external cohorts. CLL-TIM is an ensemble algorithm composed of 28 machine learning algorithms based on data from 4,149 patients with CLL. The model is capable of dealing with heterogeneous data, including the high rates of missing data to be expected in the real-world setting, with a precision of 72% and a recall of 75%. To address concerns regarding the use of complex machine learning algorithms in the clinic, for each patient with CLL, CLL-TIM provides explainable predictions through uncertainty estimates and personalized risk factors.

4 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
CNCarsten U. Niemann
Carsten U. Niemann
CCCaspar da Cunha-Bang
Caspar da Cunha-Bang
MHMarie Helleberg
Marie Helleberg
SOSisse R. Ostrowski
Sisse R. Ostrowski
CBChristian Brieghel
Christian Brieghel
Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.

24 December 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
LMLarry Mansouri
Larry Mansouri
BTBirna Thorvaldsdottir
Birna Thorvaldsdottir
LSLesley-Ann Sutton
Lesley-Ann Sutton
GKGeorgios Karakatsoulis
Georgios Karakatsoulis
MMManja Meggendorfer
Manja Meggendorfer
RBRichard Rosenquist Brandell
Richard Rosenquist Brandell
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.7%) patients at frequencies ranging from 2.3–9.8% with mutations in NOTCH1 being the most frequent. In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT. In multivariate analysis of Binet stage A patients, performed separately for IGHV-mutated (M-CLL) and unmutated CLL (U-CLL), a different spectrum of gene alterations independently predicted short TTFT within the two subgroups. While SF3B1 and XPO1 mutations were independent prognostic variables in both U-CLL and M-CLL, TP53, BIRC3 and EGR2 aberrations were significant predictors only in U-CLL, and NOTCH1 and NFKBIE only in M-CLL. Our findings underscore the need for a compartmentalized approach to identify high-risk patients, particularly among M-CLL patients, with potential implications for stratified management.

8 March 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
MAMichael Asger Andersen
Michael Asger Andersen
CECasper Tabassum Eriksen
Casper Tabassum Eriksen
CBChristian Brieghel
Christian Brieghel
JBJorne Lionel Biccler
Jorne Lionel Biccler
CCCaspar da Cunha-Bang
Caspar da Cunha-Bang
CNCarsten Utoft Niemann
Carsten Utoft Niemann

7 May 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CBChristian Brieghel
Christian Brieghel
KAKathrine Aarup
Kathrine Aarup
MTMathias H. Torp
Mathias H. Torp
MAMichael A. Andersen
Michael A. Andersen
CYChristina W. Yde
Christina W. Yde
CNCarsten U. Niemann
Carsten U. Niemann
Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated (single-hit) or multiple (multi-hit) TP53 aberrations remains unclear, particularly in the context of targeted agents. Patients and Methods: We performed deep sequencing of TP53 using baseline samples collected from 51 TP53 aberrant patients treated with ibrutinib in a phase II study (NCT01500733). Results: We identified TP53 mutations in 43 patients (84%) and del(17p) in 47 (92%); 9 and 42 patients carried single-hit and multi-hit TP53, respectively. The multi-hit TP53 subgroup was enriched with younger patients who had prior treatments and unmutated immunoglobulin heavy-chain variable region gene status. We observed significantly shorter overall survival, progression-free survival (PFS), and time-to-progression (TTP) in patients with multi-hit TP53 compared with those with single-hit TP53. Clinical outcomes were similar in patient subgroups stratified by 2 or >2 TP53 aberrations. In multivariable analyses, multi-hit TP53 CLL was independently associated with inferior PFS and TTP. In sensitivity analyses, excluding mutations below 1% VAF demonstrated similar outcome. Results were validated in an independent population-based cohort of 112 patients with CLL treated with ibrutinib. Conclusions: In this study, single-hit TP53 defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit TP53 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit TP53 CLL. See related commentary by Bomben et al., p. 4462